ストックスクリーナーアプリを入手
0.7102
2.18%
-0.0158
プレマーケット:
.71
-0.0002
-0.03%
前日終値:
$0.726
開ける：
$0.75
24時間の取引高:
133.20K
Relative Volume:
0.12
時価総額：
$1.51M
収益：
$4.70M
当期純損益:
$-4.99M
株価収益率:
-0.1106
EPS:
-6.42
ネットキャッシュフロー:
$-5.29M
1週間 パフォーマンス:
+4.59%
1か月 パフォーマンス:
-38.24%
6か月 パフォーマンス:
-73.50%
1年 パフォーマンス:
-53.88%
1日の値動き範囲:
$0.672
$0.75
1週間の範囲:
$0.598
$0.75
52週間の値動き範囲:
$0.4519
$7.20
Salarius Pharmaceuticals Inc Stock (SLRX) Company Profile
名前
Salarius Pharmaceuticals Inc
セクター
電話
346-772-0346
住所
2450 HOLCOMBE BLVD, HOUSTON
SLRX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SLRX
Salarius Pharmaceuticals Inc
|
0.7102 | 1.44M | 4.70M | -4.99M | -5.29M | -6.42 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Salarius Pharmaceuticals Inc Stock (SLRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2020-04-27 | 開始されました | Ladenburg Thalmann | Buy |
Salarius Pharmaceuticals Inc (SLRX) 最新ニュース
What analysts say about Salarius Pharmaceuticals Inc. stockHigh-yield investments - jammulinksnews.com
What drives Salarius Pharmaceuticals Inc. stock priceSuperior risk-adjusted returns - jammulinksnews.com
Is Salarius Pharmaceuticals Inc. a good long term investmentBreakthrough capital growth - Autocar Professional
Salarius Pharmaceuticals amends merger agreement to allow debt-for-equity exchange - Investing.com
Salarius Pharmaceuticals Inc. Stock Analysis and ForecastBreakthrough stock performance - printweek.in
Salarius Pharmaceuticals (NASDAQ:SLRX) Trading Up 0.1% – What’s Next? - Defense World
How Salarius Pharmaceuticals Inc. stock performs during market volatilityFree Stock Market Return Analysis - Newser
Why Salarius Pharmaceuticals Inc. stock attracts strong analyst attentionFree Expert-Led Investment Training - Newser
What makes Salarius Pharmaceuticals Inc. stock price move sharplyShort Squeeze Radar - Newser
Salarius Pharmaceuticals granted additional extension to regain Nasdaq compliance - MSN
Salarius Pharmaceuticals Granted Extension to Regain Compliance With Nasdaq's Stockholders' Equity Requirement - MarketScreener
Salarius Pharmaceuticals Receives Extension for Nasdaq Compliance and Updates on Planned Merger with Decoy Therapeutics - Quiver Quantitative
SLRX gets Nasdaq extension; equity deadline moves to late-July 2025 | NDSN SEC FilingForm 8-K - Stock Titan
Salarius Pharmaceuticals Granted Additional Extension to - GlobeNewswire
Salarius Secures Critical Nasdaq Extension Amid $2.5M Equity Requirement Challenge - Stock Titan
Salarius Pharmaceuticals’ Seclidemstat Demonstrates - GlobeNewswire
Salarius Pharmaceuticals, Inc. Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published Studies - MarketScreener
Salarius Pharmaceuticals’ Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published Studies - GlobeNewswire
Breakthrough Studies Support Salarius Cancer Drug Effectiveness While Clinical Trials Show Promise - Stock Titan
Salarius Pharmaceuticals reports progress in LSD1 inhibitor study, merger with Decoy Therapeutics. - AInvest
Salarius Pharmaceuticals shareholders approve reverse stock split and share issuance - Investing.com Nigeria
Salarius Pharmaceuticals Approves Reverse Stock Split - TipRanks
Why Is Salarius Pharmaceuticals Stock (SLRX) Up 110% Today? - The Globe and Mail
Salarius Pharmaceuticals Stock Price, Quotes and Forecasts | NASDAQ:SLRX - Benzinga
What's Going On With Salarius Pharmaceuticals Shares Today? - Benzinga
Salarius Granted Nasdaq Extension To Regain Compliance With Listing Standards - Nasdaq
Salarius Pharmaceuticals Soars 149.6% on Nasdaq Extension - AInvest
Salarius Pharmaceuticals Granted Nasdaq Compliance Extension - TipRanks
Salarius Pharmaceuticals adjusts merger terms amid market shifts By Investing.com - Investing.com Nigeria
Salarius Pharmaceuticals adjusts merger terms amid market shifts - Investing.com Australia
Salarius Pharmaceuticals Enters Second Amendment To Merger Agreement With DecoySEC Filing - MarketScreener
Comparing Schrödinger (NASDAQ:SDGR) & Salarius Pharmaceuticals (NASDAQ:SLRX) - Defense World
Salarius Pharmaceuticals Inc (SLRX) 財務データ
収益
当期純利益
現金流量
EPS
0.51%
大文字化:
|
ボリューム (24 時間):